Dataset Information

Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.

ABSTRACT:

Background

Many kinase inhibitors have been approved as cancer therapies. Recently, libraries of kinase inhibitors have been extensively profiled, thus providing a map of the strength of action of each compound on a large number of its targets. These profiled libraries define drug-kinase networks that can predict the effectiveness of untested drugs and elucidate the roles of specific kinases in different cellular systems. Predictions of drug effectiveness based on a comprehensive network model of cellular signalling are difficult, due to our partial knowledge of the complex biological processes downstream of the targeted kinases.

Results

We have developed the Kinase Inhibitors Elastic Net (KIEN) method, which integrates information contained in drug-kinase networks with in vitro screening. The method uses the in vitro cell response of single drugs and drug pair combinations as a training set to build linear and nonlinear regression models. Besides predicting the effectiveness of untested drugs, the KIEN method identifies sets of kinases that are statistically associated to drug sensitivity in a given cell line. We compared different versions of the method, which is based on a regression technique known as elastic net. Data from two-drug combinations led to predictive models, and we found that predictivity can be improved by applying logarithmic transformation to the data. The method was applied to the A549 lung cancer cell line, and we identified specific kinases known to have an important role in this type of cancer (TGFBR2, EGFR, PHKG1 and CDK4). A pathway enrichment analysis of the set of kinases identified by the method showed that axon guidance, activation of Rac, and semaphorin interactions pathways are associated to a selective response to therapeutic intervention in this cell line.

Conclusions

We have proposed an integrated experimental and computational methodology, called KIEN, that identifies the role of specific kinases in the drug response of a given cell line. The method will facilitate the design of new kinase inhibitors and the development of therapeutic interventions with combinations of many inhibitors.

SUBMITTER: Tran TP

PROVIDER: S-EPMC4094402 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.

Tran Trish P TP Ong Edison E Hodges Andrew P AP Paternostro Giovanni G Piermarocchi Carlo C

BMC systems biology 20140625

<h4>Background</h4>Many kinase inhibitors have been approved as cancer therapies. Recently, libraries of kinase inhibitors have been extensively profiled, thus providing a map of the strength of action of each compound on a large number of its targets. These profiled libraries define drug-kinase networks that can predict the effectiveness of untested drugs and elucidate the roles of specific kinases in different cellular systems. Predictions of drug effectiveness based on a comprehensive network ...[more]

PMID: 24961498

Similar Datasets

Project description:Microbiome data are becoming increasingly available in large health cohorts, yet metabolomics data are still scant. While many studies generate microbiome data, they lack matched metabolomics data or have considerable missing proportions of metabolites. Since metabolomics is key to understanding microbial and general biological activities, the possibility of imputing individual metabolites or inferring metabolomics pathways from microbial taxonomy or metagenomics is intriguing. Importantly, current metabolomics profiling methods such as the HMP Unified Metabolic Analysis Network (HUMAnN) have unknown accuracy and are limited in their ability to predict individual metabolites. To address this gap, we developed a novel metabolite prediction method, and we present its application and evaluation in an oral microbiome study. The new method for predicting metabolites using microbiome data (ENVIM) is based on the elastic net model (ENM). ENVIM introduces an extra step to ENM to consider variable importance (VI) scores, and thus, achieves better prediction power. We investigate the metabolite prediction performance of ENVIM using metagenomic and metatranscriptomic data in a supragingival biofilm multi-omics dataset of 289 children ages 3-5 who were participants of a community-based study of early childhood oral health (ZOE 2.0) in North Carolina, United States. We further validate ENVIM in two additional publicly available multi-omics datasets generated from studies of gut health. We select gene family sets based on variable importance scores and modify the existing ENM strategy used in the MelonnPan prediction software to accommodate the unique features of microbiome and metabolome data. We evaluate metagenomic and metatranscriptomic predictors and compare the prediction performance of ENVIM to the standard ENM employed in MelonnPan. The newly developed ENVIM method showed superior metabolite predictive accuracy than MelonnPan when trained with metatranscriptomics data only, metagenomics data only, or both. Better metabolite prediction is achieved in the gut microbiome compared with the oral microbiome setting. We report the best-predictable compounds in all these three datasets from two different body sites. For example, the metabolites trehalose, maltose, stachyose, and ribose are all well predicted by the supragingival microbiome.

Dataset Information

Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.

Background

Results

Conclusions

Publications

Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets